Apogee Therapeutics Inc (APGE)
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel biologics for inflammatory and immunology-related diseases in the United States. The company’s pipeline includes Zumilokibart (APG777), a subcutaneous extended half-life monoclonal antibody being studied for atopic dermatitis in phase 2 trials and for asthma and eosinophilic esophagitis in phase 1 trials. Apogee is also advancing APG279 for atopic dermatitis, APG273 for asthma and chronic obstructive pulmonary disease, and APG808, another subcutaneous extended half-life monoclonal antibody targeting IL-4Ra for type 2 allergic diseases. The company was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Next Earnings Date | Price-to-Book Ratio | Market Cap | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-APGE
|
Not available
|
Not available
|
Not available
|
Good
|
November 16, 2026
|
8.5x
|
10.186 B
|
0.1%
|
77.5%
|
42.6
|
82.9%
|
